

Oracle Argus Safety

Argus Safety E2B(R3) Best Practices



Release 8.4.4
G36547-01
February 2025

ORACLE®

Copyright © 2022, 2025, Oracle and/or its affiliates.

This software and related documentation are provided under a license agreement containing restrictions on use and disclosure and are protected by intellectual property laws. Except as expressly permitted in your license agreement or allowed by law, you may not use, copy, reproduce, translate, broadcast, modify, license, transmit, distribute, exhibit, perform, publish, or display any part, in any form, or by any means. Reverse engineering, disassembly, or decompilation of this software, unless required by law for interoperability, is prohibited.

The information contained herein is subject to change without notice and is not warranted to be error-free. If you find any errors, please report them to us in writing.

If this is software, software documentation, data (as defined in the Federal Acquisition Regulation), or related documentation that is delivered to the U.S. Government or anyone licensing it on behalf of the U.S. Government, then the following notice is applicable:

U.S. GOVERNMENT END USERS: Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs) and Oracle computer documentation or other Oracle data delivered to or accessed by U.S. Government end users are "commercial computer software," "commercial computer software documentation," or "limited rights data" pursuant to the applicable Federal Acquisition Regulation and agency-specific supplemental regulations. As such, the use, reproduction, duplication, release, display, disclosure, modification, preparation of derivative works, and/or adaptation of i) Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs), ii) Oracle computer documentation and/or iii) other Oracle data, is subject to the rights and limitations specified in the license contained in the applicable contract. The terms governing the U.S. Government's use of Oracle cloud services are defined by the applicable contract for such services. No other rights are granted to the U.S. Government.

This software or hardware is developed for general use in a variety of information management applications. It is not developed or intended for use in any inherently dangerous applications, including applications that may create a risk of personal injury. If you use this software or hardware in dangerous applications, then you shall be responsible to take all appropriate fail-safe, backup, redundancy, and other measures to ensure its safe use. Oracle Corporation and its affiliates disclaim any liability for any damages caused by use of this software or hardware in dangerous applications.

Oracle®, Java, MySQL, and NetSuite are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Intel and Intel Inside are trademarks or registered trademarks of Intel Corporation. All SPARC trademarks are used under license and are trademarks or registered trademarks of SPARC International, Inc. AMD, Epyc, and the AMD logo are trademarks or registered trademarks of Advanced Micro Devices. UNIX is a registered trademark of The Open Group.

This software or hardware and documentation may provide access to or information about content, products, and services from third parties. Oracle Corporation and its affiliates are not responsible for and expressly disclaim all warranties of any kind with respect to third-party content, products, and services unless otherwise set forth in an applicable agreement between you and Oracle. Oracle Corporation and its affiliates will not be responsible for any loss, costs, or damages incurred due to your access to or use of third-party content, products, or services, except as set forth in an applicable agreement between you and Oracle.

Contents

Preface

Documentation accessibility	i
Diversity and Inclusion	i
Related resources	i
Access to Oracle Support	i

1 Revision history

2 Introduction

3 Set up reporting destinations to send E2B(R3) report

Configure the EDI and Report tabs for EMA and PMDA	2
Configure the EDI and Report tab for FDA	2
Configure Attachments	3
Configure Folders	3
Configure Studies for FDA IND or Pre-ANDA reporting	4
Configure expedited rules	4

4 Configure parameters for E2B(R3) Reports and Acknowledgment

5 Customize Mappings and Validations

Preface

This preface contains the following sections:

- [Documentation accessibility](#)
- [Diversity and Inclusion](#)
- [Related resources](#)
- [Access to Oracle Support](#)

Documentation accessibility

For information about Oracle's commitment to accessibility, visit the Oracle Accessibility Program website at <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=docacc>.

Diversity and Inclusion

Oracle is fully committed to diversity and inclusion. Oracle respects and values having a diverse workforce that increases thought leadership and innovation. As part of our initiative to build a more inclusive culture that positively impacts our employees, customers, and partners, we are working to remove insensitive terms from our products and documentation. We are also mindful of the necessity to maintain compatibility with our customers' existing technologies and the need to ensure continuity of service as Oracle's offerings and industry standards evolve. Because of these technical constraints, our effort to remove insensitive terms is ongoing and will take time and external cooperation.

Related resources

For information about Oracle Argus patches, see [My Oracle Support](#).

All documentation and other supporting materials are available on the [Oracle Help Center](#).

Access to Oracle Support

To receive support assistance, determine whether your organization is a cloud or on-premises customer. If you're not sure, use Support Cloud.

Cloud customers receive support assistance through Support Cloud

Oracle customers that have purchased support have access to electronic support through Support Cloud.

Contact our Oracle Customer Support Services team by logging requests in one of the following locations:

- English interface of Oracle Life Sciences Support Cloud (<https://hsgbu.custhelp.com/>)

- Japanese interface of Oracle Life Sciences Support Cloud へようこそ (<https://hsghu-jp.custhelp.com/>)

You can also call our 24x7 help desk. For information, visit [Life Sciences Support | Oracle](#) or visit [Oracle Accessibility Learning and Support](#) if you are hearing impaired.

On-premises customers receive support assistance through My Oracle Support

Oracle customers that have purchased support have access to electronic support through My Oracle Support. For information, visit <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=info> or visit <http://www.oracle.com/pls/topic/lookup?ctx=acc&id=trs> if you are hearing impaired.

1

Revision history

Argus version	Description
8.4	First release
8.4.1	Updated the Customize Mappings and Validations section.
8.4.2	Updated the Set up reporting destinations to send E2B(R3) report and Introduction sections with FDA-specific recommendations.
8.4.3	Updated the Set up reporting destinations to send E2B(R3) report section to include the Apply EMA Special Rules parameter and added the Configure Folders section.
8.4.4	Updated the following sections: <ul style="list-style-type: none">• Configure Attachments• Configure Folders• Configure Studies for FDA IND or Pre-ANDA reporting• Configure expedited rules• Configure parameters for E2B(R3) Reports and Acknowledgment

2

Introduction

This document describes best practices and recommendations to configure the EMA, FDA, and PMDA agencies and common profile switches for the E2B(R3) reports.

3

Set up reporting destinations to send E2B(R3) report

You need to set up reporting destinations when sending E2B(R3) reports. Provide the following information in the **Agency Information** tab and **Local Company Contact** tab:

Agency Information tab

Enter name and email address information of the agency as applicable.

Local Company Contact tab

Enter name and address information of the local company contact that is responsible for ICSR submission. The following data can be updated for ICSR submission other than the mandatory fields shown in UI:

- Sender Type
- Department
- Contact Name information
 - Title
 - First Name
 - Last Name
 - Address
 - City
 - State
 - Postal Code
 - Country
 - Phone
 - Fax
 - Email Address

For more information, see:

- [Configure the EDI and Report tabs for EMA and PMDA](#)
- [Configure the EDI and Report tab for FDA](#)
- [Configure Attachments](#)
- [Configure Folders](#)
- [Configure Studies for FDA IND or Pre-ANDA reporting](#)
- [Configure expedited rules](#)

Configure the EDI and Report tabs for EMA and PMDA

The following table lists and describes the fields on the EDI and Report tabs to be set up for the EMA and PMDA profiles:

Agency Identifier	EVCTM or EVPM	PMDA
Secondary Agency/Department Identifier	Not applicable	Not applicable
File type	XML	XML
Company identifier	As applicable	As applicable
Message Profile	ICH-ICSR V3.0 MESSAGE TEMPLATE - EMA	ICH-ICSR V3.0 MESSAGE TEMPLATE - PMDA
ACK Profile	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - EMA	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - PMDA
Suppress ACK transmission	Marked	Unchecked (Default)
Transmit ICSR Attachments	Marked	Marked
Attachment Classification	As applicable	As applicable
Allowed attachment file size (in MB)	15 MB	15 MB
Allowed report size (in MB)	100 MB	AS1: 10 MB AS2: 50 MB
Incoming folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
Outgoing folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
ICSR Attachment Outgoing Folder	Not required	Not required
File Name	As required, for example: EVPM_#####.xml	As required, for example: PMDA_#####.xml
Method	E2B EDI gateway	E2B EDI gateway

Configure the EDI and Report tab for FDA

The following table lists and describes the fields on the EDI and Report tabs to be set up for the FDA profile:

Field	IND report	Pre-ANDA report	Post Marketed report
Agency Identifier	ZZFDA_PREMKT	ZZFDA_PREMKT	ZZFDA
Secondary Agency/Department Identifier	CDER_IND or CDER_IND	CDER_IND_EXEMPT_B A_BE	CDER
File type	XML	XML	XML
Company identifier	As applicable	As applicable	As applicable
Message Profile	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS

Field	IND report	Pre-ANDA report	Post Marketed report
ACK Profile	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS
Suppress ACK transmission	Unchecked (Default)	Unchecked (Default)	Unchecked (Default)
Transmit ICSR Attachments	Marked	Marked	Marked
Attachment Classification	As applicable	As applicable	As applicable
Allowed attachment file size (in MB)	15 MB	15 MB	15 MB
Allowed report size (in MB)	100 MB	AS1: 10 MB AS2: 50 MB	100 MB
Incoming folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
Outgoing folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
ICSR Attachment Outgoing Folder	Not required	Not required	Not required
File Name	As required, for example: IND_#####.xml	As required, for example: PREANDA_##### .xml	As required, for example: NDA_#####.xml
Method	E2B EDI gateway	E2B EDI gateway	E2B EDI gateway
Apply EMA Special Rules	Marked	Marked	Marked

Note

You can check the **Apply EMA Special Rules** checkbox to apply EMA special instruction rules for cases that have at least one Reporter's Country that belongs to the European Union.

Configure Attachments

The file attachment types allowed for ICH, EMA, MFDA and NMPA E2B(R3) profiles are configured in **System Configuration > Common Profile Switch > Reporting > E2B**.

The file attachment types allowed for eVAERS and FDA E2B(R3) are configured in **Flexible Re-Categorization Code Lists > codelist name MEDIATYPE** with attributes FDA and FAERS respectively.

Configure Folders

If the common profile switch **Base directory path for gateway folders** is specified, then the Base directory path can be \\10.100.80.100\Gatewaysharedfolder\. The In/Out folders then need to be specified with sub folder path such as EVPM\IN, EVPM\OUT.

The Interchange services creates folders in the format <Base folder path>\<Abbreviated Enterprise name >\<Sub folder path>. If the folder name

created by the Interchange services is not required when inserting the Abbreviated name of the Enterprise between the base directory path and the sub folder path, then the **Interchange service to exclude Enterprise abbreviated name for folder creation** parameter in the EDI tab of Reporting Destination code list needs to be marked.

If the Common profile Switch **Base directory path for gateway folders** is not specified, then In/Out folders need to be specified with an absolute path such as `\10.100.80.100\Gatewaysharedfolder\EVPM\IN`. Interchange services creates folders using the folder structure provided in the Sub folder path.

Configure Studies for FDA IND or Pre-ANDA reporting

IND Studies

Make sure to enter the clinical reference for IND studies, including the primary IND number associated with the study. Optionally, you can also add the cross-reported IND number, if applicable.

Reference Type	Country	Reference Number
CDER-IND or CBER-IND	United States	Select the Primary IND number.
Cross reported IND	United States	Enter the cross reported IND.

Pre-ANDA Studies

Make sure to enter the clinical reference for Pre-ANDA studies and include the primary IND number associated with the study.

Reference Type	Country	Reference Number
Pre-ANDA	United States	Enter the Pre-ANDA number.

Note

Cross-reported IND numbers [FDA C.5.6.r] for IND reports are auto-populated by Interchange based on the product's license configuration. Refer to the FAERS mappings in the E2B R3 mapping document for additional details. Additionally, manually configured INDs in the study will also be transmitted.

Configure expedited rules

Make sure to enter the following information in the reporting rules created for IND, Pre-ANDA and Spontaneous IND Study cases in addition to other reporting criteria that are configured in the expedited rules.

The following rules are based on the ICHICSR/E2B message type and report format. Except for the CDER-30 Day WORLD rule, all rules apply exclusively to the United States.

Rule	Reporting Destination	License Type	Time Frame	Condition
CDER-15 Day	ZZFDA/CDER	Marketed Drug	15	Serious (Event) = Yes

Rule	Reporting Destination	License Type	Time Frame	Condition
CDER-60 Day	ZZFDA/CDER	Marketed Drug	60	Case Serious = No; Any other condition as per your company's business process
CDER-5 Day	ZZFDA/CDER	Marketed Drug (for Combination Products)	5	Criteria using Advance conditions <ul style="list-style-type: none"> Remedial Action exists Case Classification = Combination Product any other condition as per your company's business process
CDER-30 Day	ZZFDA/CDER	Marketed Drug (for Combination Products)	30	Case Serious = No Criteria using Advance conditions <ul style="list-style-type: none"> Malfunction = Yes Case Classification = Combination Product Any other condition as per your company's business process
CDER-30 Day WORLD	ZZFDA/CDER	Marketed Drug (for Combination Products)	30	Case Serious = No Criteria using Advance conditions: <ul style="list-style-type: none"> Case Classification = Combination Product Malfunction = Yes Product type = Treatment/ Other Drug not administered = Yes Similar Device = Yes
IND - CDER-15 Day IND-CBER-15 Day	ZZFDA_PREM KT/CDER_IND ZZFDA_PREM KT/CBER_IND	Investigational drug	15	Event Serious =Yes and Listedness (Event) = No Study Reference Type=CDER-IND/ CBER-IND Any other condition as per your company's business process
IND - CDER-7 Day IND - CBER-7 Day	ZZFDA_PREM KT/CDER_IND ZZFDA_PREM KT/CBER_IND	Investigational drug	7	Event Serious =Yes and Listedness (Event) = No S/UL/Fatal/LT = Yes Study Reference Type=CDER-IND/ CBER-IND Any other condition as per your company's business process
Pre-ANDA	ZZFDA_PREM KT/CDER_IND_EX EMPT_BA_BE	Investigational drug	15	Event Serious =Yes and Listedness (Event) = No Study Reference Type=Pre-ANDA Any other condition as per your company's business process
IND for Post Marketed Cases	ZZFDA_PREM KT/CDER_IND or CBER_IND	Investigational drug	15 or 7	Event Serious =Yes and Listedness (Event) = No Study Reference Type=Ignore Any other condition as per your company's business process

If you are transitioning from MedWatch format to E2B(R3) for IND reporting to FDA, then it is recommended the existing rules used for reporting to FDA by updating the report form to E2B, and configure additional information required as specified above.

Note

If you are not transitioning from the MedWatch format to E2B(R3) for reporting to the FDA, we recommend modifying the `Reporting Destination > Message Profile` used for MedWatch reporting to FDA MEDWATCH 3500A DRUG TEMPLATE.

If the profile in the agency settings is changed to the FDA MEDWATCH 3500A DRUG TEMPLATE or the E2B R3 profile ICH-ICSR V3.0 MESSAGE TEMPLATE - FAERS, it is not recommended to switch back to the MedWatch paper reporting format.

If you decide to create a new agency, any case updates will be transmitted as an initial report to the new agency.

4

Configure parameters for E2B(R3) Reports and Acknowledgment

The following switches need to be reviewed and adjusted according to your requirements:

Common profile switch	Description
Default viewing format of the E2B R3 report	Allows you to configure the default view of displaying E2B(R3) in the ICSR viewer. The default value is Decoded view. The available options are XML View or HL7 View.
Default viewing format of the PMDA E2B R3 report (used with Interchange-J)	Allows you to configure the default view of displaying PMDA E2B(R3) in the ICSR viewer. The default value is Decoded view. The options available are: <ul style="list-style-type: none">• XML View• HL7 View• Paper View

Configure parameters for E2B(R3) acknowledgment

The following parameters, located in `Console > Code Lists > Argus > Reporting Destination > EDI`, affect acknowledgment (ACK) and need to be reviewed and adjusted according to your requirements:

Parameter	Description
Local time zone to process Date/Timestamp values of Ack	Allows you to configure the offset to be applied to the following elements in the acknowledgment file if the offset is missing: E2B R3 ACK file - ACK.M.4 messagedater3 PMDA Device ACK file - ACK.6 ACKCREATEDATE

5

Customize Mappings and Validations

Argus Interchange allows you to customize the mappings and validations. For details on how to customize E2B(R3) profiles, refer to the *Oracle Argus Interchange ICSR Extensibility Guide*.

Adherence to conformance rules and validation can be achieved during data entry by creating field validations in Argus Console.

For example, the below general date validations can be configured on the corresponding fields to warn user during data entry to take corrective action.

- Death Date must be greater than equal to Patient Date of Birth
- Parent date of birth must be earlier than date of birth for patient
- Date value in Date of Start of Reaction/Event must be lesser or equal to the Date of Death

For more details on how to configure field validations, refer to the *Oracle Argus Safety Administration Guide > System Configuration > Configuring Field Validations*.